Your session is about to expire
← Back to Search
Cognitive Processing Therapy for PTSD in Individuals with HIV
Study Summary
This trial will study how well an evidence-based PTSD treatment, Cognitive Processing Therapy, works to reduce HIV transmission behavior and improve HIV outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I haven't changed my mental health medication in the last 4 weeks.I experience symptoms like hallucinations or delusions.I have developmental delays or have been diagnosed with a pervasive developmental disorder.
- Group 1: Cognitive Processing Therapy-Lifesteps (CPT-L) [Group A]
- Group 2: Lifesteps [Group B]
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current cohort size of this research?
"Yes, indeed. On clinicaltrials.gov the study is listed as presently recruiting participants with an initial post date of July 13th and most recent edit on July 25th 2022. This trial seeks 60 individuals at a single location."
Are any new recruits still being welcomed into this clinical investigation?
"Affirmative. Per clinicaltrials.gov, enrollment is ongoing for this research project which was initially posted on July 13th 2022 and most recently modified on July 25th 2022. A total of 60 individuals will be recruited from a singular medical centre."
What is the fundamental purpose of this clinical experiment?
"The primary outcome of this trial, evaluated over a time frame of 18 months, will be the percentage of eligible participants. Secondary outcomes include mean scores for viral load (a measure in copies per milliliter), PTSD symptoms (measured by PCL-5 scale with 33+ being clinically significant), and WHOQOL-HIV BREF domains which score from 4 to 20 - higher indicating better quality of life."
Share this study with friends
Copy Link
Messenger